Compare Agilysys Inc (AGYS) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs BioNTech SE - ADR — how do they compare? Agilysys Inc trades at $100.12 (market cap $2.83B), while BioNTech SE - ADR trades at $101.3 (market cap $24.62B). The key difference: BioNTech SE - ADR is far larger — about 8.7× Agilysys Inc's market cap, and BioNTech SE - ADR is more actively traded (782,425 versus 126,197). Which is the better fit depends on your goals — on Pluang, investors hold Agilysys Inc for 12 Days and BioNTech SE - ADR for 58 Days on average.
| AGYS | BNTX | |
|---|---|---|
Market Cap | $2.83B | $24.62B |
Volume | 126,197 | 782,425 |
Sector | Technology | Health |
52-Week High | $141.12 | $119.34 |
52-Week Low | $62.19 | $83.89 |
Typical Hold Time | 12 Days | 58 Days |
Enterprise Value | $2.72B | $8.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $100.13, down 2.04% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong Q1 2027 results with record revenue of $87.7 million (Business Wire, 2026-07-27), beating EPS estimates, and raised its full-year outlook. Valuation ratios remain elevated with a P/E of 65.95 and P/S of 8.63, reflecting high growth expectations in the hospitality software sector.
The outlook is positive with 100% analyst buy ratings and a consensus price target of $120.75 (MarketBeat, 2026-09-02), offering ~20% upside. Key risks include high valuation sensitivity to earnings misses and competitive pressures. Subscription revenue expansion and institutional interest, such as BlackRock's $431.7 million stake acquisition (Defense World, 2026-08-26), support growth, but investors should monitor execution on guidance.
BioNTech (BNTX) trades at $96.06, down 2.64% on the day, with bearish technical signals from moving averages. The company faces fundamental challenges with negative net income margins (-63.64%) and declining revenue trends, though maintains a strong cash position of $16.78 billion. Recent news includes mixed developments with termination of a colorectal cancer trial but positive lung cancer drug data.
While analyst consensus remains strongly bullish (83% buy ratings) with a $121.83 price target, significant execution risks persist in transitioning from COVID-19 vaccines to oncology pipeline success. The stock offers potential upside if cancer therapies gain traction but carries high volatility given current profitability challenges and clinical trial uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
